Das Medizinportal     Aktuelles für medizinische Fachkreise
Menü

Das Medizinportal     Aktuelles für medizinische Fachkreise

Literatur:

Pulmonale Hypertonie

Ekkehard Grünig , Nicola Benjamin, Christina Alessandra Eichstädt

 

  1. Grünig E, Ehlken N, Hohenforst-Schmidt W, Krüger U, Krüger S, Lichtblau M, et al. Allgemeine Therapie der pulmonal arteriellen Hypertonie. Deutsch Med Wochenschr. 2014;139:S136–41.
  2. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2015.
  3. Opitz CF, Blindt R, Blumberg F, Borst MM, Bruch L, Leuchte H, et al. [Pulmonary hypertension: hemodynamic evaluation: hemodynamic evaluation - recommendations of the Cologne Consensus Conference 2010]. Deutsche medizinische Wochenschrift (1946). 2010;135 Suppl 3:S78–86.
  4. Daley E, Emson C, Guignabert C, de Waal Malefyt R, Louten J, Kurup VP, et al. Pulmonary arterial remodeling induced by a Th2 immune response. J Exp Med. 2008;205(2):361–72.
  5. Hoeper MM, Huscher D, Ghofrani HA, Delcroix M, Distler O, Schweiger C, et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. International journal of cardiology. 2013;168(2):871–80.
  6. Bossone E, Ferrara F, Grunig E. Echocardiography in pulmonary hypertension. Current opinion in cardiology. 2015;30(6):574–86.
  7. Pfarr N, Szamalek-Hoegel J, Fischer C, Hinderhofer K, Nagel C, Ehlken N, et al. Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations. Respir Res. 2011;12:99.
  8. Soubrier F, Chung WK, Machado R, Grunig E, Aldred M, Geraci M, et al. Genetics and genomics of pulmonary arterial hypertension. Journal of the American College of Cardiology. 2013;62(25 Suppl):D13–21.
  9. Grunig E, Barner A, Bell M, Claussen M, Dandel M, Dumitrescu D, et al. [Non-invasive diagnosis of pulmonary hypertension: ESC/ERS Guidelines with commentary of the Cologne Consensus Conference 2010]. Deutsche medizinische Wochenschrift (1946). 2010;135 Suppl 3:S67–77.
  10. Grunig E, Henn P, D'Andrea A, Claussen M, Ehlken N, Maier F, et al. Reference values for and determinants of right atrial area in healthy adults by 2-dimensional echocardiography. Circulation Cardiovascular imaging. 2013;6(1):117–24.
  11. Grunig E, Tiede H, Enyimayew EO, Ehlken N, Seyfarth HJ, Bossone E, et al. Assessment and prognostic relevance of right ventricular contractile reserve in patients with severe pulmonary hypertension. Circulation. 2013;128(18):2005–15.
  12. Grunig E, Weissmann S, Ehlken N, Fijalkowska A, Fischer C, Fourme T, et al. Stress Doppler echocardiography in relatives of patients with idiopathic and familial pulmonary arterial hypertension: results of a multicenter European analysis of pulmonary artery pressure response to exercise and hypoxia. Circulation. 2009;119(13):1747–57.
  13. Nagel C, Henn P, Ehlken N, D'Andrea A, Blank N, Grünig E, et al. Stress-Doppler-Echocardiography for early detection of systemic sclerosis associated pulmonary arterial hypertension. Arthritis research & therapy. 2015;17(1):165.
  14. Grunig E, Ehlken N, Hohenforst-Schmidt W, Kruger U, Kruger S, Lichtblau M, et al. [Supportive therapy in pulmonary arterial hypertension]. Deutsche medizinische Wochenschrift (1946). 2014;139 Suppl 4:S136–41.
  15. Lowe B, Grafe K, Ufer C, Kroenke K, Grunig E, Herzog W, et al. Anxiety and depression in patients with pulmonary hypertension. Psychosom Med. 2004;66(6):831–6.
  16. Harzheim D, Klose H, Pinado FP, Ehlken N, Nagel C, Grünig E, et al. Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Respir Res. 2013;14:104.
  17. Mereles D, Ehlken N, Kreuscher S, Ghofrani S, Hoeper MM, Grünig E, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation. 2006;114(14):1482–9.
  18. Marra A, Egenlauf B, Bossone E, Eichstaedt C, Grunig E, Ehlken N. Principles of Rehabilitation and Reactivation: Pulmonary Hypertension. Respiration; international review of thoracic diseases. 2015.
  19. Ehlken N, Lichtblau M, Klose H, Weidenhammer J, Fischer C, Grünig E, et al. Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial. Eur Heart J. 2015.
  20. Meyer S, McLaughlin VV, Seyfarth HJ, Bull TM, Vizza CD, Gomberg-Maitland M, et al. Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey. Eur Respir J. 2013;41(6):1302–7.
  21. Olsson KM, Delcroix M, Ghofrani HA, Tiede H, Grünig E, Speich R, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation. 2014;129(1):57–65.
  22. Klose H, Opitz C, Bremer H, Ewert R, Bonderman D, Grünig E, et al. [Targeted therapy of pulmonary arterial hypertension (PAH)]. Deutsche medizinische Wochenschrift (1946). 2014;139 Suppl 4:S142–50.
  23. Galie N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J. 2009;30(4):394–403.
  24. Ghofrani HA, D'Armini AM, Grünig E, Grimminger F, Hoeper MM, Jansa P, Kim NH, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. The New England journal of medicine. 2013;369(4):319–29.
  25. Galie N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371(9630):2093–100.
  26. Simonneau G, Rubin LJ, Galie N, Barst RJ, Fleming TR, Frost AE, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008;149(8):521–30.
  27. Pulido T, Adzerikho I, Galie N, Ghofrani HA, Grünig E et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. The New England journal of medicine. 2013;369(9):809–18.
  28. Simonneau G, Torbicki A, Hoeper MM, Delcroix M, Karlocai K, Galie N, et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012;40(4):874–80.
  29. Ghofrani HA, Galie N, Grimminger F, Grünig E, Humbert M, Jing ZC, et al. Riociguat for the treatment of pulmonary arterial hypertension. The New England journal of medicine. 2013;369(4):330–40.
  30. Galie N, Barbera JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. The New England journal of medicine. 2015;373(9):834–44.
  31. Mayer E, Jenkins D, Lindner J, D'Armini A, Kloek J, Meyns B, et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. The Journal of thoracic and cardiovascular surgery. 2011;141(3):702–10.